Page 5 - Bladder Cancer Session
P. 5
Non-muscle Invasive Disease
Non-muscle-invasive Bladder Cancer Pembrolizumab for the treatment of patients with high-risk (HR) non-
muscle-invasive bladder cancer (NMIBC) unresponsive to BCG: Extended follow-up of KEYNOTE-057 cohort A
Lancet Oncol 2021; 22: 919–30
BalarAV et al. SeoHK. UAA Congress 2020